RxDoctor Payments Data

Vishal Vyas, MD

Clinical Cardiac Electrophysiology · Houma, LANPI 1154516938

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $747 of the $1,222 with a category attached, or 61.1%. 10 manufacturers reported payments, led by Medtronic at 43.4% of the total. Reporting peaked in 2024 at $554 and has fallen 81.5% since, to $102 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in LA, where the typical reported total is $18,132.

$1,222in general payments, 2019–2025

Across 40 payments — averaging $30.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$531
  • Abbott$288
  • Novartis$99
  • Pfizer$79
  • E.r. Squibb & Sons, L.L.C.$64
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$40
  • plus $121 from 4 others

What the payments were for

  • Consulting fees$47539%
  • Food & beverage$74761%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,222 in reported general payments places this provider in the 0th percentile of 43 clinical cardiac electrophysiology providers in Louisiana.

See all clinical cardiac electrophysiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$28,816
Medicare patients
205
Services billed
581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban202$230,158
EntrestoSacubitril/Valsartan16$22,933
XareltoRivaroxaban22$22,456
Praluent PenAlirocumab32$15,539
Repatha SureclickEvolocumab24$12,725
Ezetimibe43$846
Metoprolol Succinate122$829
Rosuvastatin Calcium56$690
Atorvastatin Calcium79$574
Carvedilol76$468
Furosemide67$314
ClopidogrelClopidogrel Bisulfate26$300
Atenolol29$262
Metoprolol Tartrate23$186
Isosorbide Mononitrate ErIsosorbide Mononitrate19$172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$79$230,158202 claims
NovartisEntresto$99$22,93316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 0th percentile of 43 clinical cardiac electrophysiology providers in Louisiana.

Other clinical cardiac electrophysiology in Houma

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →